文献速递脊髓损伤康复神经康复

鞘内与口服巴氯芬治疗成人脊髓损伤痉挛的系统综述

Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events.
PubMed 文献 · Arch Phys Med Rehabil · 2022-06-22

该系统综述纳入98项研究共1943例成人脊髓损伤伴痉挛患者,评估鞘内与口服巴氯芬的疗效、剂量与安全性。巴氯芬可有效改善痉挛结局指标,鞘内给药疗效更高,但仅4项随机双盲安慰剂对照试验,证据质量有限。常见不良事件包括肌无力和疲劳。

要点

  • 巴氯芬是脊髓损伤后最常用的抗痉挛药物,鞘内给药疗效高于口服。
  • 仅4项随机双盲安慰剂对照试验,多数疗效数据来自小型研究。
  • 常见不良事件为肌无力和疲劳,可能影响生活质量。

核心结论

  • 巴氯芬是脊髓损伤后最常用的抗痉挛药物,可有效改善痉挛结局指标,鞘内给药疗效更高。
  • 缺乏大型安慰剂对照双盲临床试验,多数疗效数据来自小型研究。
  • 不良事件较多,可能对生活质量产生负面影响。
  • 需要开展巴氯芬与替代治疗的比较性随机对照试验。

研究设计与样本

  • 系统综述检索PubMed和Cochrane数据库1970至2018年文献,最终纳入98项研究共1943例患者。
  • 纳入标准为成人脊髓损伤伴痉挛患者,干预为口服或鞘内巴氯芬,结局包括疗效、剂量和不良事件。
  • 纳入随机对照试验、观察性研究和病例报告,排除Meta分析和系统综述。
  • 仅4项为随机双盲安慰剂对照试验。

主要发现

  • 39项研究评估Modified Ashworth Scale(MAS;34项研究)和Penn Spasm评分(Penn Spasm Frequency;19项研究)变化。
  • MAS平均降低1.7±1.3,Penn Spasm评分平均降低1.6±1.4。
  • 34项MAS研究中仅6项、19项Penn Spasm评分研究中仅2项分析口服巴氯芬。
  • 43项研究报道不良事件,肌无力和疲劳常见。
  • 少数研究评估神经兴奋性降低对残余运动功能和日常生活活动的影响。

关键数值与推荐

  • MAS平均降低1.7±1.3(34项研究)。
  • Penn Spasm评分平均降低1.6±1.4(19项研究)。

临床怎么用

  • 巴氯芬可用于成人脊髓损伤后痉挛的治疗,鞘内给药可能提供更高疗效。
  • 使用中需监测肌无力和疲劳等不良事件,并关注其对生活质量的影响。
  • 因缺乏大型高质量试验,临床决策需结合个体情况并考虑替代治疗。

局限性

  • 仅4项随机双盲安慰剂对照试验,多数疗效数据来自小型研究且跨越不同病因。
  • 少数研究评估痉挛改善对残余运动功能和日常生活活动的影响。
  • 缺乏巴氯芬与替代治疗的比较性随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the efficacy, dosing, and safety profiles of intrathecal and oral baclofen in treating spasticity after spinal cord injury (SCI). DATA SOURCES: PubMed and Cochrane Databases were searched from 1970-2018 with keywords baclofen, spinal cord injury, and efficacy. STUDY SELECTION: The database search yielded 588 sources and 10 additional relevant publications. After removal of duplicates, 398 publications were screened. DATA EXTRACTION: Data were extracted using the following population, intervention, comparator, outcomes, and study designs criteria: studies including adult patients with SCI with spasticity; the intervention could be oral or intrathecal administration of baclofen; selection was inclusive for control groups, surgical management, rehabilitation, and alternative pharmaceutical agents; outcomes were efficacy, dosing, and adverse events. Randomized controlled trials, observational studies, and case reports were included. Meta-analyses and systematic reviews were excluded. DATA SYNTHESIS: A total of 98 studies were included with 1943 patients. Only 4 randomized, double-blinded, and placebo-controlled trials were reported. Thirty-nine studies examined changes in the Modified Ashworth Scale (MAS; 34 studies) and Penn Spasm scores (Penn Spasm Frequency; 19 studies), with average reductions of 1.7±1.3 and 1.6±1.4 in individuals with SCI, respectively. Of these data, a total of 6 of the 34 studies (MAS) and 2 of the 19 studies (Penn Spasm Frequency) analyzed oral baclofen. Forty-three studies addressed adverse events with muscle weakness and fatigue frequently reported. CONCLUSIONS: Baclofen is the most commonly-prescribed antispasmodic after SCI. Surprisingly, there remains a significant lack of large, placebo-controlled, double-blinded clinical trials, with most efficacy data arising from small studies examining treatment across different etiologies. In the studies reviewed, baclofen effectively improved spasticity outcome measures, with increased efficacy through intrathecal administration. Few studies assessed how reduced neural excitability affected residual motor function and activities of daily living. A host of adverse events were reported that may negatively affect quality of life. Comparative randomized controlled trials of baclofen and alternative treatments are warranted because these have demonstrated promise in relieving spasticity with reduced adverse events and without negatively affecting residual motor function.

来源:Arch Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Dietz N, Wagers S, Harkema SJ, et al. Intrathecal and Oral Baclofen Use in Adults With Spinal Cord Injury: A Systematic Review of Efficacy in Spasticity Reduction, Functional Changes, Dosing, and Adverse Events. Arch Phys Med Rehabil. 2022. PMID: 35750207. doi:10.1016/j.apmr.2022.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。